肝内CD206+巨噬细胞参与晚期病毒相关性肝病的炎症
研究对比健康供者(n=19)与病毒相关性肝硬化患者(HBV、HBV/HDV或HCV;n=15)的肝内CD14+髓系细胞,发现肝病时CD14+HLA-DRhiCD206+细胞扩增并自发产生TNFα和GM-CSF,该积聚在小鼠模型中可被口服抗生素消除。结论认为病毒相关性慢性肝炎炎症由非内毒素耐受的促炎CD14+HLA-DRhiCD206+髓系细胞与易位细菌产物相互作用驱动。
要点
- 病毒相关性肝硬化患者肝内CD14+HLA-DRhiCD206+髓系细胞扩增,自发产生TNFα和GM-CSF。
- 该细胞仅对细菌TLR激动剂呈增强促炎反应,且对内毒素耐受更抵抗。
- 人源化小鼠中该细胞积聚可被口服抗生素消除,提示肠源细菌产物参与。
核心结论
- 病毒相关性慢性肝炎炎症由非内毒素耐受的促炎CD14+HLA-DRhiCD206+髓系细胞与易位细菌产物相互作用驱动。
研究设计与样本
- 研究纳入健康供者(n=19)和病毒相关性肝硬化患者(HBV、HBV/HDV或HCV;n=15),对其肝内CD14+髓系细胞进行表型、分子和功能表征。
- 研究还使用人源化小鼠肝炎症模型观察CD14+HLA-DRhiCD206+细胞的肝内富集及口服抗生素的影响。
主要发现
- 肝病与肝内活化髓系细胞扩增相关,主要为促炎CD14+HLA-DRhiCD206+细胞,可自发产生TNFα和GM-CSF。
- 这些细胞仅对细菌TLR激动剂表现出增强的促炎反应,且对内毒素诱导的耐受更抵抗。
- 人源化小鼠肝炎症模型中检测到CD14+HLA-DRhiCD206+细胞的肝内富集,口服抗生素治疗后该积聚被消除。
临床怎么用
- 作者认为,阐明该机制为开发特异性靶向CD206+髓系细胞的病毒相关性肝病治疗策略开辟了道路。
- 作者的研究结果支持使用口服抗生素改善这些患者的肝脏炎症(原文为Lay summary表述)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver inflammation is key in the progression of chronic viral hepatitis to cirrhosis and hepatocellular carcinoma. The magnitude of viral replication and the specific anti-viral immune responses should govern the degree of inflammation, but a direct correlation is not consistently found in chronic viral hepatitis patients. We aim to better define the mechanisms that contribute to chronic liver inflammation. METHODS: Intrahepatic CD14+ myeloid cells from healthy donors (n=19) and patients with viral-related liver cirrhosis (HBV, HBV/HDV or HCV; n=15) were subjected to detailed phenotypic, molecular and functional characterisation. RESULTS: Unsupervised analysis of multi-parametric data showed that liver disease was associated with the intrahepatic expansion of activated myeloid cells mainly composed of pro-inflammatory CD14+HLA-DRhiCD206+ cells, which spontaneously produced TNFα and GM-CSF. These cells only showed heightened pro-inflammatory responses to bacterial TLR agonists and were more refractory to endotoxin-induced tolerance. A liver-specific enrichment of CD14+HLA-DRhiCD206+ cells was also detected in a humanised mouse model of liver inflammation. This accumulation was abrogated following oral antibiotic treatment, suggesting a direct involvement of translocated gut-derived microbial products in liver injury. CONCLUSIONS: Viral-related chronic liver inflammation is driven by the interplay between non-endotoxin-tolerant pro-inflammatory CD14+HLA-DRhiCD206+ myeloid cells and translocated bacterial products. Deciphering this mechanism paves the way for the development of therapeutic strategies specifically targeting CD206+ myeloid cells in viral-related liver disease patients. Lay summary: Viral-related chronic liver disease is driven by intrahepatic pro-inflammatory myeloid cells accumulating in a gut-derived bacterial product-dependent manner. Our findings support the use of oral antibiotics to ameliorate liver inflammation in these patients.
引用
- Tan-Garcia A, Wai LE, Zheng D, et al. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. J Hepatol. 2017. PMID: 28483682. doi:10.1016/j.jhep.2017.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。